[Retracted] Efficacy and Safety of Peginterferon <i>α</i>-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Indicators</td><td class="align_center">Control group (<i>n</i> = 26)</td><td class="align_center">Tenofovir group (<i>n</i> = 26)</td><td class="align_center">Entecavir group (<i>n</i> = 26)</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">Complete response</td><td class="align_center">10</td><td class="align_center">20</td><td class="align_center">17</td></tr><tr><td class="align_left">Partial response</td><td class="align_center">2</td><td class="align_center">3</td><td class="align_center">3</td></tr><tr><td class="align_left">No response</td><td class="align_center">14</td><td class="align_center">3</td><td class="align_center">6</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Distribution of response at 12 months after treatment in the three groups.</div>

Contrast Media & Molecular Imaging

tab5

Table 5

Table 5: [Retracted] Efficacy and Safety of Peginterferon <i>α</i>-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C 

Contrast Media & Molecular Imaging

[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Table 5